Literature DB >> 2462849

Post-ERCP acute necrotizing pancreatitis.

I Nordback1, I Airo.   

Abstract

An analysis of acute necrotizing pancreatitis (ANP) after endoscopic retrograde cholangiopancreatography (ERCP) was carried out. The incidence of ANP was 0.5% (5/914) for ERCP and 0.5% (2/370) for endoscopic sphincterotomies (EST). All the five patients were obese, middle-aged or older women. Four had a suspicion of common bile duct stones and the fifth a pancreatic tumour as an indication for ERCP. Two had most probably a functional sphincteric disorder and the third was without clear pathological findings. In the remaining two cases the bile duct cannulation failed and repeated pancreatic duct cannulation occurred; while in one case the pancreatic duct was not cannulated. The four pancreatographies were normal and without parenchymal opacification. Symptoms of acute pancreatitis started within 6 hours after ERCP. The pancreatitis was severe by Ranson criteria and necrotizing by evaluation at laparotomy. All the patients showed bacterial growth either in bile, blood or ascitic fluid early in the course of pancreatitis (E. coli, Str. faecalis or Klebsiella pneumoniae). The possible pathogenetic factors of post-ERCP ANP are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462849

Source DB:  PubMed          Journal:  Ann Chir Gynaecol        ISSN: 0355-9521


  3 in total

Review 1.  Heretical thoughts on the pathogenesis of acute pancreatitis.

Authors:  M Keynes
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

2.  Post-ERCP pancreatitis: reduction by routine antibiotics.

Authors:  S Räty; J Sand; M Pulkkinen; M Matikainen; I Nordback
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

3.  New endoscopic treatment for chronic pancreatitis, using contrast media containing ulinastatin and prednisolone.

Authors:  M Ohwada; N Watanabe; M Maeda; M Gotoh; J Teramoto; H Moriya; T Nakajima; T Okamoto; N Tsuji; D Kobayashi; Y Niitsu
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.